Loading provider…
Loading provider…
Orthopaedic Surgery Physician in Gainesville, FL
NPI: 1285662940Primary Practice Location
UF HEALTH SHANDS HOSPITAL
4101 Nw 89th Blvd, Gainesville, FL
Primary Employer
UF Health Physicians
ufhealth.org
HQ Phone
Get MD Mark's Phone Numberphone_androidMobile
Get MD Mark's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardFL State Medical License
FL State Medical License
1991 - 2027

American Board of Orthopaedic Surgery
Orthopaedic Surgery
Mass General Brigham/Massachusetts General Hospital/Harvard Medical School
Fellowship • Musculoskeletal Oncology
1990 - 1991
University of Texas Medical Branch Hospitals
Residency • Orthopaedic Surgery
1985 - 1990
University Of Florida College Of Medicine
med.ufl.edu
Medical School
Until 1985
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 62 | 89 |
| 2 | 99204New patient office or other outpatient visit, 45-59 minutes | 51 | 51 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 43 | 48 |
| 4 | 99203New patient outpatient visit, total time 30-44 minutes | 11 | 11 |
Heterotopic ossification and other perioperative complications of acetabular fractures.
Authors: Daum, W J, Scarborough, M T, Gordon, W, Uchida, T
Journal: J Orthop Trauma
CORR Insights ®: Intramedullary nailing of femoral diaphyseal metastases: is it necessary to protect the femoral neck?
Authors: Mark T. Scarborough
Publication Date: 2015-04
Long-term followup of patients with autogenous resection arthrodesis of the knee.
Authors: Robert Wolf
Journal: Clin Orthop Relat Res
Lead Sponsor: ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Docetaxel, RADIATION: Radiation Therapy, DRUG: Paclitaxel, BIOLOGICAL: Trastuzumab, DRUG: Nab-paclitaxel, PROCEDURE: Lumpectomy, BIOLOGICAL: Trastuzumab Emtansine, PROCEDURE: Mastectomy, BIOLOGICAL: Pertuzumab
Lead Sponsor: Alliance Foundation Trials, LLC.
Collaborators: Patient-Centered Outcomes Research Institute, Duke University, M.D. Anderson Cancer Center, Dana-Farber Cancer Institute, New York University, Washington University School of Medicine, The University of Texas MD Anderson Cancer Center, Rising Tide Foundation, Breast Cancer Research Foundation
Intervention / Treatment: OTHER: Active Monitoring, OTHER: Surgery
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), Division of Cancer Control, NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP), Canadian Cancer Trials Group
Intervention / Treatment: OTHER: Weight Loss Intervention, OTHER: Health Education Program